Halozyme Therapeutics HALO
NASDAQ HALO
$123.50 -1.33 (-1.07%)
As of: Oct 22, 2026 · 2:39 PM EDT

Halozyme Therapeutics (HALO) Interest Paid (2012 - 2013)

Updated

Analysis

Halozyme Therapeutics (HALO) Interest Paid (2012 - 2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Paid (Qtr)
1 Eli Lilly 1,167.69 Bn 1,136.27 Bn 19.71 Bn -
2 Johnson & Johnson 648.01 Bn 567.87 Bn 17.30 Bn -
3 AbbVie 503.52 Bn 476.63 Bn 12.70 Bn -
4 Merck 367.68 Bn 322.06 Bn 12.21 Bn -
5 Novartis Ag 303.32 Bn 267.31 Bn 11.24 Bn 339.00 Mn
6 Astrazeneca 269.17 Bn 242.86 Bn 12.86 Bn 1.07 Bn
7 Amgen 242.30 Bn 197.70 Bn 7.24 Bn -
8 Gilead Sciences 195.24 Bn 169.44 Bn 6.22 Bn -
9 Pfizer 172.59 Bn 119.24 Bn 10.94 Bn 1.25 Bn
10 Halozyme Therapeutics 14.49 Bn 13.09 Bn 401.83 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 1.57 Mn
Sep 30, 2013 566,250.00
Jun 30, 2013 566,250.00
Mar 31, 2013 396,938.00
Dec 31, 2012 19,000.00
API Access

Halozyme Therapeutics Interest Paid API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-paid&ticker=HALO&period=max&api_key=YOUR_API_KEY